The findings will provide knowledge regarding potential biomarkers that can be used to predict progression to rheumatoid arthritis (RA) among early undifferentiated arthritis (UA) patients. These biomarkers will enable RA treatment to be targeted to patients at high risk of developing RA in the very early stages of disease using a precision medicine approach, thus enhancing the chances of significantly improved outcomes, possibly even remission, and contributing to more cost-effective treatment of RA.
|Effective start/end date||8/1/22 → 8/31/23|
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (7R21AR076026-03)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.